OPHIDION, INC is developing a new class of safe and effective drugs targeting some of the most important receptors in the central nervous system. They are targeting relief of the symptoms of schizophrenia, ADHD, Parkinson’s disease, and Alzheimer’s disease, as well as addiction and anxiety. The founder launched the company in the Pasadena Bioscience Collaborative and located at TechVentures when she joined the Lehigh University faculty.

Categories

Industry Biomedical
Sub-industry
Focus Areas
Focus Areas - detailed Schizophrenia, ADHD, Parkinson’s, Alzheimer’s disease, addiction, anxiety, smoking cessation

University

University Lehigh, Rockefeller, Caltech
Principal Investigator Julie Miwa - Lehigh

Company

Web http://nep.benfranklin.org/ophidion-inc-2/
Web http://pasadenabiosci.org/companies/ophidion/
Address Ben Franklin TechVentures, 116 Research Dr., Bethlehem PA 18015
Phone 610.758.3079 (Office at Lehigh University)
Email moc.oibnoidihpo|awim.eiluj#moc.oibnoidihpo|awim.eiluj

Markets

Smoking Cessation
Cholinergic Drugs

Key People

Timeline

2009 - Founded

Intellectual Property



No files attached to this page.

Add a New Comment